Clinical trial · Interventional
Interest of Virtual Reality to Prevent Cancer Patient Anxiety Before Chemotherapy or an Invasive Act
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the REV clinical trial is to evaluate the impact of a virtual reality exposure to decrease patient anxiety before chemotherapy or an invasive act. If positive, the access to virtual reality exposure is aimed to be used as standard of care at Lyon's hospital to improve cancer patient well-being in a drug-free manner. The majority of cancer patients lives with high level of anxiety as soon as diagnosed. This level anxiety is particularly high before invasive acts but also before chemotherapy by side effects anticipation. Hypnosis is a highly interesting drug-free approach to decrease patient's anxiety. It however requires on site specialists to be available whenever needed. Virtual reality provides a distractive environment enabled to shift patient focus. It can support a switch of patient mindset by providing positive emotions. Since 5 years, this disruptive technology is being more and more used as medical support thanks to a new generation of headsets enabling improved performance at cheaper prices. Many publications have now demonstrated the positive impact of virtual reality to take in charge patients' pain or pre-operational anxiety.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anxiety | — | UNRESOLVED | — |
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Chemotherapy Effect | — | UNRESOLVED | — |
| Head Cancer Neck | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Virtual reality exposure | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Virtual reality exposure
- description
- Virtual reality exposure just before an oncological procedure (invasive act or a chemotherapy)
- interventionNames
- Behavioral: Virtual reality exposure
Primary outcomes (1)
- measure
- Difference of anxiety using the State-Trait Anxiety Inventory before oncologic procedure
- timeFrame
- Before an invasive act or a chemotherapy
- description
- Difference of anxiety before and after a virtual reality exposure using the State-Trait Anxiety Inventory (STAI-Y; A-State Scale) before patients undergo an oncologic procedure (invasive act or chemotherapy (C1D1).
Secondary outcomes (5)
- measure
- Difference of anxiety using a self-evaluation anxiety inventory before oncologic procedure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: For all patients: * Patient Study Information and written informed consent * Social Security Affiliation For breast cancer cohort : * Adult patient (\>18 years) * Histological or cytological proven breast cancer * Eligible to an adjuvant or neo-adjuvant IV chemotherapy given every 2 to 3 weeks (with protocol doxorubicin- cyclophosphamide, docetaxel-cyclophosmadide, docetaxel-cyclophosphamide-trastuzumab, docetaxel, carboplatine, trastuzumab, epirubicin-cyclophosphamide, etc) * Therapeutic strategy validated in multidisciplinary meeting * First chemotherapy cure (C1D1) not initiated yet * Patients with a complete healing after resection (for adjuvant chemotherapy) * Patients that do not report residual pain with an intensity \> 4. For head, neck and bladder cancer cohort : * Adult patient (\>18 years) * Histological or cytological proven head, neck or bladder cancer * Patient eligible for an adjuvant or neoadjuvant based on cisplatin. * Therapeutic strategy validated in multidisciplinary meeting * First chemotherapy cure (C1D1) not initiated yet * Patients with a complete healing after resection. * Patients that do not report residual pain with an intensity \> 4. For invasive act leading to potential anxiety cohort : * Adult patient (\>18 years) * Histological or cytological proven cancer * Patient with a planned hospitalization at oncological unit * Eupneic patient * Afebrile patient Patient for whom an invasive act leading to potential anxiety is planned (excluding percutaneous implantable chamber) : * Puncture * Deep biopsy * Sounding * Endoscopy without general anesthesia * myelogram Exclusion Criteria: * Patient with a consciousness disturbance or a spatio-temporal disturbance * Claustrophobic patient * Patient with a non-stabilized psychiatric pathology * Patient with seizure crisis background * Patient with a visual or hearing disturbance that is not compatible with video watching and sound listening * Patients with out-of range clinical parameters (arterial pressure, cardiac frequency,..) * Patients with out-of range blood parameters that are not compatible with chemotherapy or an invasive act. * Patient with a life expectancy below 3 months. * Impossibility to track and follow patient (any reason) * Patient deprived of liberty or subjected to guardianship
References
Publications (0)
Data not yet available